Edition:
India

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

19.90USD
17 Nov 2017
Change (% chg)

$0.18 (+0.91%)
Prev Close
$19.72
Open
$19.84
Day's High
$19.93
Day's Low
$19.39
Volume
119,774
Avg. Vol
165,265
52-wk High
$33.20
52-wk Low
$10.83

Latest Key Developments (Source: Significant Developments)

Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces pricing of public offering of common stock.Says ‍priced public offering of 6.3 million shares of its common stock at a public offering price of $24.00 per share​.  Full Article

Intellia Therapeutics announces proposed public offering of common stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc NTLA.O:Intellia therapeutics announces proposed public offering of common stock.Intellia therapeutics inc - ‍has commenced an underwritten public offering of $150 million of its common stock​.  Full Article

Intellia Therapeutics Q3 loss per share $‍0.44​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc ::Intellia therapeutics announces third quarter 2017 financial results.Q3 collaboration revenue $7.3 million versus $4.9 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/Cas9.Qtrly loss per share $‍0.44​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Intellia Therapeutics Q3 revenue $65 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc -:Intellia Therapeutics announces third quarter 2017 financial results.Q3 revenue $65 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/CAS9.  Full Article

Atlas Venture Fund reports 12.3 pct stake in Intellia Therapeutics
Friday, 10 Feb 2017 

Atlas Venture Fund IX, L.P:Atlas Venture Fund IX, L.P. reports a 12.3 percent passive stake in Intellia Therapeutics Inc as of December 31, 2016 -sec filing.  Full Article

Intellia Therapeutics qtrly net loss of $6.9 mln vs net loss of $3 mln in Q2 2015
Friday, 5 Aug 2016 

Intellia Therapeutics Inc : Intellia therapeutics reports financial results for second quarter 2016 . Collaboration revenue was $4.2 million in q2 2016, compared to $1.4 million in same period of 2015 .Qtrly net loss of $6.9 million versus net loss of $3 million in q2 2015.  Full Article

Orbimed Advisors reports 7.40% stake in Intellia Therapeutics
Saturday, 21 May 2016 

Intellia Therapeutics Inc :Orbimed Advisors LLC reports 7.40% stake in Intellia Therapeutics as of May 11, 2016 - sec filing.  Full Article

Regeneron Pharmaceuticals reports 7.7 pct passive stake in Intellia Therapeutics
Thursday, 12 May 2016 

Regeneron Pharmaceuticals Inc:Regeneron Pharmaceuticals Inc reports 7.7 pct passive stake in Intellia Therapeutics Inc as of May 11 - SEC Filing.  Full Article

Intellia Therapeutics shares open 22.2 pct above IPO price in debut
Friday, 6 May 2016 

: Intellia Therapeutics Inc shares open at $22.00 in market debut, above IPO price of $18.00 Further company coverage: [NTLA.O] ((Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780;)).  Full Article

Intellia Therapeutics announces pricing of initial public offering
Friday, 6 May 2016 

Intellia Therapeutics:Says pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $18 per share.Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager.Intellia's common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol "NTLA" on May 6, 2016.  Full Article